MicroRNAs (miRNAs) are important regulators of differentiation and cell fate decisions. Multiple miRNAs, such as microRNA-200 (miR-200) and miR-155, have been identified as suppressors or promoters of epithelial-mesenchymal transition (EMT) ([@mvx017-B1]). In addition, several studies have described roles of miRNAs in endothelial-mesenchymal transition (EndMT), which is important for heart development and various pathological processes ([@mvx017-B2]). We have previously reported that transforming growth factor-β (TGF-β) induces mesenchymal genes including α-smooth muscle actin (α-SMA) by activating Rho signals and myocardin-related transcription factor A (MRTF-A), and that constitutively active miR-31 is a positive regulator of TGF-β-induced EndMT and EndMT-associated secretory phenotype (EndMT-SP) in MS-1 mouse pancreatic microvascular endothelial cells ([@mvx017-B2], [@mvx017-B3]).

miR-23, miR-24 and miR-27, members of miR-23/24/27 clusters, are highly conserved vertebrate miRNAs and are involved in various biological processes ([@mvx017-B4]). Mammals have two miR-23/24/27 clusters: miR-23a∼27a∼24-2 and miR-23b∼27b∼24-1. Members of miR-23/24/27 have been proposed to have important roles in angiogenesis ([@mvx017-B5]). In addition, deregulated expression of these miRNAs and cancer-related roles have been described in many studies with varying results ([@mvx017-B9]). miR-23 and miR-27 are shown to facilitate EMT in several types of cancer including lung cancer ([@mvx017-B9]). We also previously reported that TGF-β induces the expression of miR-23a in A549 lung cancer cells ([@mvx017-B10]). However, in contrast to their roles in EMT, the roles of miR-23/24/27 in EndMT have not been well characterized. In the present study, we studied the effects of TGF-β on expression levels of miR-23/24/27 and potential contribution of miR-27 to TGF-β-driven EndMT in MS-1 endothelial cells.

miRNA microarray analysis (H.I.S. & A.K., article in preparation) showed that TGF-β increased the expression of miR-23b, miR-24 and miR-27b in MS-1 cells ([Fig. 1a](#mvx017-F1){ref-type="fig"}). The effects on miR-23a and miR-27a were not remarkable. Next, we investigated the roles of endogenous miR-27b in EndMT by inhibiting endogenous miR-27 activity. Locked nucleic acid (LNA) miR-27b inhibitor (LNA-miR-27b) abolished miR-27b activity in MS-1 cells ([Fig. 1b](#mvx017-F1){ref-type="fig"}). miR-27b inhibitor suppressed induction of mesenchymal markers, α-SMA and SM22α, by TGF-β ([Fig. 1c](#mvx017-F1){ref-type="fig"}). In contrast, miR-27b inhibitor did not attenuate induction of conventional Smad target genes, Smad7, Fibronectin1, and PAI-1 and downregulation of endothelial markers, VEGFR2 and CD34 ([Fig. 1d and e](#mvx017-F1){ref-type="fig"}). These results demonstrated that TGF-β induces the expression levels of miR-23b/24-1/27b but not of miR-23a/24-2/27a in MS-1 cells and that miR-27 positively regulates mesenchymal gene induction by TGF-β. Fig. 1**miR-27b is a positive regulator of EndMT induced by TGF-β in MS-1 endothelial cells. (a)** Effects of TGF-β on miR-23/24/27 expression levels, determined by miRNA microarray analysis (TGF-β2, 1 ng/ml, 72 h). **(b)** Inhibition of miR-27b activity by miR-27b inhibitor in MS-1 cells. MS-1 cells were transfected with LNA control miRNA inhibitor (LNA-NC) or LNA miR-27b inhibitor (LNA-miR-27b, 50 nM) and miRNA sensor vectors, and subjected to dual luciferase reporter assay after 48 h. **(c--e)** Effects of miR-27 inhibition on TGF-β-mediated gene expression changes (c, EndMT genes; d, conventional TGF-β target genes; and e, endothelial cell-specific genes), determined by qRT-PCR analysis. MS-1 cells transfected with LNA miRNA inhibitors were stimulated with TGF-β2 (1 ng/ml, 72 h). Error bars represent SDs. \**P* \< 0.05. Experimental procedures and primer information are described in [Supplementary Materials](#sup1){ref-type="supplementary-material"} and [Supplementary Tables S5 and S6](#sup1){ref-type="supplementary-material"}.

In order to identify miR-27 targets during TGF-β-mediated EndMT at a transcriptome-wide level, we analysed the RNAseq data using MS-1 cells treated with miR-27b inhibitor and/or TGF-β, reported in our previous study ([@mvx017-B3]). In consistent with widespread inhibitory effects of miRNAs on target gene expression, mRNA levels of potential miR-27 target genes with both conserved and poorly conserved target sites generally increased by miR-27 silencing ([Fig. 2a](#mvx017-F2){ref-type="fig"} and [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Gene ontology (GO) analysis showed that LNA-miR-27b-sensitive miR-27 target genes are related to diverse molecular functions, such as ion binding, transcriptional regulation, and regulation of phosphorylation ([Fig. 2b](#mvx017-F2){ref-type="fig"} and [Supplementary Table S2](#sup1){ref-type="supplementary-material"}). Fig. 2**Transcriptome-wide identification of miR-27 target genes. (a)** Cumulative distribution plots of mRNA fold changes of miR-27 target genes predicted by TargetScan (right, conserved; middle, poorly conserved) and other expressed genes (left) by miR-27 inhibition in MS-1 cells. *P* values were calculated by one-sided Kolmogorov-Smirnov test. **(b)** GO analysis of miR-27 target genes upregulated by LNA-miR-27b. **(c)** Occurrence of representative LNA-miR-27b-sensitive miR-27 targets in top 50 pathway maps from MetaCore Pathway Map analysis. **(d)** Connectivity maps of gene sets obtained from GSEA for LNA-miR-27b-induced gene expression changes using C2CGP gene set collection (FDR \< 0.0001). Right and left nodes represent gene sets with enrichment in LNA-miR-27b samples and in LNA-NC samples, respectively. Enrichments with and without TGF-β treatment are mapped to the node borders and inner node area, respectively. Gene sets without edges are not shown. **(e)** Sequence alignment between miR-27b and its putative-binding site in mouse Elk1 3'UTR. **(f)** Suppression of Elk1 3'UTR by miR-27b. Dual luciferase assay was performed in HEK293T cells using pri-miR-27b expression vector and wild-type or mutated Elk1 3'UTR reporter vector (shown in panel (e)) according to previous reports ([@mvx017-B11]).

To analyse functions of miR-27 targets in the context of known biological pathways, we performed pathway map analysis using MetaCore software. Representative miR-27 target genes frequently observed in the pathway maps enriched for LNA-miR-27b-sensitive miR-27 targets included several transcriptional factors such as CREB1 and Elk1 and various signaling regulators, including phosphoinositide 3-kinase, c-Jun N-terminal kinase and p38 mitogen-activated protein kinase ([Fig. 2c](#mvx017-F2){ref-type="fig"} and [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Such miR-27 target genes also included multiple transcription factors, such as Elk1, EPAS1, ARNT, CREB1, SP1 and GATA2, important for endothelial function ([Supplementary Fig. S1](#sup1){ref-type="supplementary-material"}). Gene set enrichment analysis (GSEA) also uncovered an association between LNA-miR-27b-dependent gene expression changes and gene sets associated with hypoxia and Elk1 paralogue, Elk3 ([Fig. 2d](#mvx017-F2){ref-type="fig"}). Since Elk1 is a ternary complex factor of the ETS-domain family, which competes with MRTFs for binding to serum response factor (SRF) and acts as a myogenic repressor ([@mvx017-B14], [@mvx017-B15]), we next focused on Elk1. Reporter assay of Elk1 3' untranslated region (3'UTR) confirmed that miR-27b targets Elk1 3'UTR depending on the predicted target site ([Fig. 2e and f](#mvx017-F2){ref-type="fig"}). These results suggest that miR-27 may facilitate TGF-β-driven EndMT through Elk1 suppression and subsequent MRTF-A activation in MS1 cells.

In addition, we found that miR-27 targets VAV3, a regulator of actin remodeling and MRTF-A activity ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Considering our previous report describing that VAV3 is regulated by another EndMT-promoting miRNA, miR-31 (*3*), VAV3 may be combinatorially regulated by miR-27 and miR-31. Although miR-31 is required for induction of EndMT-SP, i.e. induction of multiple inflammatory chemokines and cytokines including CCL17, CX3CL1, IL-6 and Angptl2 ([@mvx017-B3]), the effects of miR-27 inhibition on EndMT-SP were weak relative to miR-31 inhibition ([Supplementary Fig. S2](#sup1){ref-type="supplementary-material"}).

We further systematically analysed TGF-β-dependent suppression of miR-27 target genes, which may be accompanied with induction of miR-27b by TGF-β. Comparison of GO terms enriched in genes downregulated by TGF-β and GO terms enriched in miR-27 target genes downregulated by TGF-β and upregulated by LNA-miR-27b suggested that genes associated with semaphorin receptor activities are suppressed by TGF-β in a miR-27-dependent fashion ([Fig. 3a](#mvx017-F3){ref-type="fig"} and [Supplementary Table S4](#sup1){ref-type="supplementary-material"}). This gene set included Neuropilin 2 (Nrp2), Plexin A2 (PlxnA2) and Plexin D1 (PlxnD1). We confirmed that miR-27b targets 3'UTRs of Nrp2, PlxnA2 and PlxnD1 as well as Elk1 ([Fig. 3b](#mvx017-F3){ref-type="fig"} and [Supplementary Fig. S3](#sup1){ref-type="supplementary-material"}). These findings suggest that TGF-β-induced EndMT is associated with miRNA-mediated alteration of semaphorin receptor activities. Fig. 3**miR-27b regulates semaphorin receptors. (a)** Top 5 GO (molecular function) terms enriched in miR-27 target genes downregulated by TGF-β and upregulated by LNA-miR-27b, obtained from MetaCore analysis. **(b)** Suppression of 3'UTRs of Nrp2, PlxnA2 and PlxnD1 by miR-27b, analysed as in [Figure 2f](#mvx017-F2){ref-type="fig"}. Sequences of mutated 3'TR are shown in [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}.

In conclusion, we demonstrated that miR-27b is a positive mediator of EndMT induced by TGF-β, adding a novel function of miR-27 in vascular biology. Relationships between miR-27 and some of the targets identified in this report, Elk1, Nrp2, PlxnA2, and PlxnD1, are maintained in mammals and zebrafish (see [Supplementary Materials](#sup1){ref-type="supplementary-material"}), suggesting that regulation of these targets by miR-27 may contribute to conserved developmental processes. In contrast to EndMT-promoting activity of miR-27 observed in our study, a previous report described that miR-23 restricts differentiation from endocardial cells to endocardial cushion cells and cardiac valve formation ([@mvx017-B16]). In the developing heart, miR-27b expression is observed in only myocardium but not endocardial cushions and increases in the later developmental stages ([@mvx017-B17]). Thus, miR-23 and miR-27 may differentially modulate EndMT in embryonic heart development and adult pathology.

We identified Elk1 as a novel target of miR-27. Another report has shown that miR-143 regulates plasticity and fate of vascular smooth muscle cells by targeting Elk1 ([@mvx017-B18]). These findings suggest that multiple miRNAs are tightly integrated into a core transcriptional network involved in smooth muscle differentiation and proliferation. Our analysis also demonstrated that miR-27b regulates several semaphorin receptors Nrp2, PlxnA2 and PlxnD1, suggesting another novel feature of TGF-β-induced EndMT. miR-23 and miR-27 have been shown to promote endothelial cell sprouting and angiogenesis by targeting various angiogenesis regulators, Sprouty2, SEMA6A and Dll4 (*6--8*). Since Plexin A2 is a receptor for SEMA6A, coordinate regulation of both semaphorin ligands and semaphorin receptors may underlie angiogenic phenotypes of miR-27. Furthermore, Nrp2 is shown to negatively regulate contractility of vascular smooth muscle cells ([@mvx017-B19]). Thus, suppression of Nrp2 by miR-27 may be associated with acquisition of contractile phenotype during EndMT. Further analysis would shed light on the importance of miR-27 and related members in EndMT and EndMT-associated pathological processes. These findings may offer development of therapeutic approach to manipulate EndMT.
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